BACKGROUND: Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent.
PURPOSE: To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes.
DATA SOURCES: Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov with no restriction by trial status or language.
STUDY SELECTION: Eligible randomized trials assigned patients hospitalized for COVID-19 to higher- versus lower-dose anticoagulation.
DATA EXTRACTION: 20 eligible trials provided data in a prospectively agreed format. Two further studies were included based on published data. The primary outcome was all-cause mortality 28 days after randomization. Secondary outcomes were progression to invasive mechanical ventilation or death, thromboembolic events, and major bleeding.
DATA SYNTHESIS: Therapeutic- compared with prophylactic-dose anticoagulation with heparins reduced 28-day mortality (OR, 0.77 [95% CI, 0.64 to 0.93]; I2 = 29%; 11 trials, 6297 patients, of whom 5456 required low or no oxygen at randomization). The ORs for 28-day mortality were 1.21 (CI, 0.93 to 1.58; I2 = 0%) for therapeutic-dose compared with intermediate-dose anticoagulation (6 trials, 1803 patients, 843 receiving noninvasive ventilation at randomization) and 0.95 (CI, 0.76 to 1.19; I2 = 0%; 10 trials, 3897 patients, 2935 receiving no or low oxygen at randomization) for intermediate- versus prophylactic-dose anticoagulation. Treatment effects appeared broadly consistent across predefined patient subgroups, although some analyses were limited in power. Higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events, but a greater risk for major bleeding.
CONCLUSION: Therapeutic-dose compared with prophylactic-dose anticoagulation reduced 28-day mortality. Mortality was similar for intermediate-dose compared with prophylactic-dose anticoagulation and higher for therapeutic-dose compared with intermediate-dose anticoagulation, although this comparison was not estimated precisely.
PRIMARY FUNDING SOURCE: No direct funding. (PROSPERO: CRD42020213461).
| Discipline Area | Score |
|---|---|
| Hospital Doctor/Hospitalists |  |
| Internal Medicine | |
| Intensivist/Critical Care |  |
| Hemostasis and Thrombosis | Coming Soon... |
This confirms prior evidence and current guidelines in favor of treatment-dose anticoagulation for non-critically ill patients hospitalized with COVID, and a lack of benefit for critically ill patients. It's not emphasized by the authors, but the findings suggest the benefit of treatment-dose AC extends to NIV.
Noteworthy that therapeutic anticoagulation has that effect; however, the abstract buries the lead a bit. There's high significance in sicker groups, with less so as patients become less critically ill. It's not significant for the vast majority of hospitalized patients.
Well done MA but this is NOT new information.
The crucial issue is to extract a clinically useful message. It's not clear it will be easy beyond current thinking - full in less sick and prophylactic in sicker patients (likely MV).
It's difficult to know what to do with these data - are they still applicable in today's COVID-infected world? The bottom line is confusing.
